【摘要】 [目的]探讨卵巢癌组织的DNA含量(DI)和细胞增殖水平(SPF)与临床病理特征及预后的关系。[方法]应用流式细胞术检测45例卵巢癌患者的新鲜癌组织中DI及SPF。[结果]45例患者中,22例为异倍体。DI为0.90~3.56,中位1.10±0.20。SPF中位11.4%±2.3%。SPF<5%为23.9%,SPF5%～14.5%为38.4%,SPF值>14.5%为37.7%。晚期、透明细胞癌患者DNA异倍体率及DI与SPF均高于早期及其它病理类型患者,但无统计学差异;卵巢癌FIGO分期、病理类型及血清CA125水平与DNA倍体、DI、SPF无关;DNA倍体、DI及SPF与卵巢癌病理分级具有显著相关性。单因素COX分析显示,DNA倍体、DI与卵巢患者的生存期无显著相关性。SPF与生存期显著相关(P=0.009)。[结论]应用流式细胞术检测卵巢癌DNA含量及SPF能为高SPF及低分化、透明细胞癌的卵巢癌患者的预后判断提供重要信息。更多还原

【Abstract】 Purpose] To investigate the relationship among DNA content DNA index(DI), S-phase fraction(SPF)analysis with the clinicopathological features and prognosis of ovarian carcinoma. [Methods] DI and SPF in 45 fresh specimens of ovarian carcinoma pathologically proved were measured by flow cytometry. [Results] Of 45 cases with ovarian carcinoma 22 cases were heteroploid(48.9%), median DI was 1.10±0.20 ranged 0.90 to 3.56 and median SPF was 11.4%±2.3%. The SPF<5% account for 5%~14.5%; >14.5%, 23.9%; and 38.4%, 37.7%. DNA aneuploid, DI, SPF in advanced stage, and clear cell carcinoma were higher than those in early stage, and other pathological types, but with no significant difference. FIGO stage, pathological type and level of CA125, all had no relationship with aneuploid, DI, SPF, but close relationship with histological type. DNA aneuploid and DI had no relationship with survival rate, SPF had close relationship with survival rate(P=0.099). [Conclusion] Using flowcytometry to detect DNA content and SPF in patients with ovarian carcinoma may provid important prognostic information for patients with clear cell carcinoma, low differenciation and high level of SPF.更多还原